Equillium Q2 Loss Narrows to $4.7M; Cash Runway Extended to 2029
EQ has more than doubled off its 52-week low of $0.756.
Summary
Equillium's Q2 loss beat expectations and cash runway extended to 2029, but significant warrant overhang remains.
Key Events · Earnings and Guidance · EQ
-
Q2 Loss Beats Consensus
Net loss of $4.7 million ($0.04/share) versus consensus of $5.9 million ($0.05/share).
-
Cash Runway Extended to 2029
Cash and equivalents of $57.2 million as of June 30, 2026, up from $30.3 million at year-end 2025, driven by the $35 million March private placement.
-
Significant Warrant Overhang
48.5 million pre-funded warrants outstanding plus 35.1 million shares subject to milestone closing, representing potential dilution of over 130% of current shares outstanding.
-
Authorized Shares Doubled
Stockholders approved an increase in authorized common shares from 200 million to 400 million on May 28, 2026.
Analysis · EQ · Life Sciences
Equillium reported a Q2 net loss of $4.7 million, beating consensus by $1.2 million, and disclosed $57.2 million in cash as of June 30, 2026. Management now expects the cash to fund operations into 2029, a significant extension from the prior 12-month guidance. The balance sheet was strengthened by a $35 million private placement in March 2026, but the company also carries substantial potential dilution from 48.5 million pre-funded warrants and 35.1 million shares subject to a milestone closing. The stock trades at $2.04, well below the $3.20 closing price used for option intrinsic value calculations at quarter-end.
At the time of this filing, EQ was trading at $2.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.1M. The 52-week trading range was $0.76 to $3.54. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.